Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.

[1]  P. Grundy,et al.  Identification of a minimal region of loss on the short arm of chromosome 1 in Wilms tumor , 2007, Genes, chromosomes & cancer.

[2]  M. Gessler,et al.  Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis , 2007, Genes, chromosomes & cancer.

[3]  D. Machin,et al.  Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. , 2006, European journal of cancer.

[4]  K Fenwick,et al.  Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse , 2006, The Journal of pathology.

[5]  N. Breslow,et al.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Colella,et al.  Genome‐wide loss of heterozygosity analysis of WT1–wild‐type and WT1‐mutant Wilms tumors , 2005, Genes, chromosomes & cancer.

[7]  P. Voûte,et al.  Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Green,et al.  The treatment of stages I-IV favorable histology Wilms' tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Kelsey,et al.  Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bentley,et al.  Fine Mapping of Wilms’ Tumors With 16q Loss of Heterozygosity Localizes the Putative Tumor Suppressor Gene to a Region of 6.7 Megabases , 2003, Annals of Surgical Oncology.

[11]  I. Tomlinson,et al.  Loss of heterozygosity analysis: Practically and conceptually flawed? , 2002, Genes, chromosomes & cancer.

[12]  Dieter Harms,et al.  Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. , 2002, Medical and pediatric oncology.

[13]  M. Gessler,et al.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. , 2001, The American journal of pathology.

[14]  A. Kelsey,et al.  The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study , 2000, British Journal of Cancer.

[15]  S. Avigad,et al.  High frequency of loss of heterozygosity for 1p35-p36 (D1S247) in Wilms tumor. , 2000, Cancer genetics and cytogenetics.

[16]  P. Scambler,et al.  Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. , 1998, British Journal of Cancer.

[17]  M. Gessler,et al.  Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters , 1998, Genes, chromosomes & cancer.

[18]  H. B. Marsden,et al.  Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Breslow,et al.  Loss of Heterozygosity for Chromosomes 16q and Ip in Wilms' Tumors Predicts an Adverse Outcome' , 2022 .

[20]  N. Hastie,et al.  The genetics of Wilms' tumor--a case of disrupted development. , 1994, Annual review of genetics.

[21]  C. Heyting,et al.  Chromosome 11 Putative Tumor Suppressor Regions , Is Limited to Loss of Heterozygosity in Wilms ' Tumors , Studied for Six Updated , 2006 .